Ignite Creation Date:
2025-12-24 @ 3:02 PM
Ignite Modification Date:
2025-12-25 @ 8:02 PM
Study NCT ID:
NCT01784159
Status:
TERMINATED
Last Update Posted:
2023-07-13
First Post:
2013-02-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ASpirin for Patients With SEPsis and SeptIc Shock
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D018805', 'term': 'Sepsis'}, {'id': 'D012772', 'term': 'Shock, Septic'}], 'ancestors': [{'id': 'D007239', 'term': 'Infections'}, {'id': 'D018746', 'term': 'Systemic Inflammatory Response Syndrome'}, {'id': 'D007249', 'term': 'Inflammation'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D012769', 'term': 'Shock'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001241', 'term': 'Aspirin'}], 'ancestors': [{'id': 'D012459', 'term': 'Salicylates'}, {'id': 'D062385', 'term': 'Hydroxybenzoates'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'placebo'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 167}}, 'statusModule': {'whyStopped': 'Terminated: The study was stopped prematurely and will not be resumed due to the higher number of bleeding cases in the intervention group, as recomended by the Data Safety Monitoring Board on February 7, 2023.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2019-03-27', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-07', 'completionDateStruct': {'date': '2023-01-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-07-12', 'studyFirstSubmitDate': '2013-02-01', 'studyFirstSubmitQcDate': '2013-02-04', 'lastUpdatePostDateStruct': {'date': '2023-07-13', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-02-05', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2022-12-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Difference between the Sequential Organ Failure Assessment (SOFA) Score on the seventh day of ICU stay and baseline (DeltaSOFA D7-D1).', 'timeFrame': '7 days', 'description': 'To evaluate whether the aspirin use reduces the intensity of organic dysfunction. measured by the variation of the SOFA score starting from the day of admission to the seventh day. The Sequential Organ Failure Assessment (SOFA) Score ranges between 0 and 24.'}], 'secondaryOutcomes': [{'measure': 'Mechanical ventilation free days;', 'timeFrame': '28 days', 'description': 'To evaluate if the aspirin use reduces the time of mechanical ventilation, that ranges between 0 and 28 days.'}, {'measure': 'Vasopressor free days', 'timeFrame': '28 days', 'description': 'To evaluate if the aspirin use reduces the days using vasoressors, that ranges between 0 and 28 days.'}, {'measure': 'Intensive Care Unit (ICU) free days', 'timeFrame': '28 days', 'description': 'Length of stay in the ICU, that ranges between 0 and 28 days'}, {'measure': 'Hospital free days', 'timeFrame': '28 days', 'description': 'Length of stay in the hospital, that ranges between 0 and 28 days'}, {'measure': 'Renal replacement therapy', 'timeFrame': '28 days', 'description': 'Length of stay in renal replacement therapy, that ranges between 0 and 28 days'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['ICU', 'Sepsis', 'Aspirin', 'Septic shock'], 'conditions': ['Sepsis']}, 'referencesModule': {'references': [{'pmid': '39982179', 'type': 'DERIVED', 'citation': 'Almeida TML, Freitas FGR, Figueiredo RC, Houly SG, Azevedo LCP, Cavalcanti AB, Damiani LP, Svicero BS, Souza MA, Bustamante CLS, Ramos FJS, Alves RSV, Atallah FC, Jackiu M, Pacheco ES, Schmidt RC, Serra FSC, Tomotani DYV, Zampieri FG, Machado FR; BRICNET. Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial. Crit Care Med. 2025 Feb 1;53(2):e269-e281. doi: 10.1097/CCM.0000000000006564. Epub 2025 Feb 21.'}]}, 'descriptionModule': {'briefSummary': 'This Randomized, pragmatic, multicentric with blinding of patients and health professionals, intention-to-treat analysis has by primary endpoint to evaluate whether the aspirin use reduces the intensity of organic dysfunction measured by the variation of the SOFA score starting from the day of admission to the seventh day. Secundary endpoint: To evaluate if the aspirin use reduces the time of mechanical ventilation, length of stay in the ICU and in the hospital. In addition, to evaluate the safety of its administration regarding the occurrence of bleeding.\n\nThe data will be collected directly from the chart of the patients admitted to the ICU.\n\nData quality assurance will be made through periodic verification, aiming for complete and consistent data. The centers will receive periodic reports for adequacy of potentially inconsistent or incomplete data.\n\nThe baseline SOFA of patients with sepsis is 8.8 with a standard deviation of 3. The expected reduction in the control group in the SOFA at day 7 is 2 points. Considering a power of 80% and a level of significance of 0.05, it is estimated that 109 patients will be needed in each group. A total of 218 patients will compose the sample.\n\nAll analyzes will follow the intention-to-treat principle. We will evaluate the effect of aspirin compared to placebo on primary and binary outcomes by means of relative risks, 95% confidence intervals and chi-square tests. For continuous outcomes with normal distribution, we will present the mean difference, 95% confidence interval and P value calculated by t test. For continuous outcomes with asymmetric distribution, we will perform Wilcoxon test.', 'detailedDescription': 'Design Randomized, pragmatic, multicentric with blinding of patients and health professionals.\n\nBias control Allocation secrecy with web randomization. Blinding of patients and health professionals. Intention-to-treat analysis.\n\nPrimary endpoint To evaluate whether the aspirin use reduces the intensity of organic dysfunction measured by the variation of the SOFA score starting from the day of admission to the seventh day.\n\nSecondary endpoint To evaluate if the aspirin use reduces the time of mechanical ventilation, time with vasopressors, time in renal replacement therapy, length of stay in the ICU and in the hospital. In addition, to evaluate the safety of its administration regarding the occurrence of bleeding.\n\nEligibility\n\nInclusion criteria:\n\nThe three criteria below must be present:\n\n1. Signature of informed consent\n2. Patients must be older than 18 years old\n3. Diagnosis of sepsis and/or septic shock for less than 48 hours with at least one of the following organ dysfunctions:\n\n * Lactate above 4mmol/L (36mg/dL)\n * Thrombocytopenia \\< 100,000/mm3 or reduction \\> 50% in the count in the last 3 days\n * PaO2/FiO2 \\< 200 without signs of apparent volume overload\n * Hypotension MAP \\< 65mmHg refractory to volume replacement with the need to use vasopressor\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Impossibility to use the intestinal tract\n3. Death perspective in less than 24 hours\n4. Patients in the end of their lives or in exclusive palliative care\n5. Patients with active bleeding\n6. Prior study participation\n7. Known allergy to aspirin\n8. Active peptic ulcer\n9. Previous use of antiplatelet agents in the last 7 days\n10. Previous use of AINEs in the last 7 days, except for dipyrone.\n11. Hemorrhagic stroke in the last 7 days or central nervous system surgery in the last 72 hours.\n12. Platelets \\<30,000 cells/mm3.\n13. Large surgery in the last 24 hours if the attending surgeon judges that the risk of bleeding is high enough that aspirin cannot be used.\n14. Ophthalmologic surgery postoperative and transurethral resection of the prostate at the discretion of the attending physician.\n15. Hepatic cirrhosis or previous liver disease with altered prothrombin activity, manifested by INR above 2.0 or other previous coagulopathies.\n16. Severe head injury in the last 7 days.\n17. Use or indication of anticoagulation.\n\nStudy intervention The treatments to be compared in the study are a dose of 200 mg of aspirin daily for 7 days and placebo. Both look identical.\n\nStudy outcomes\n\nPrimary outcomes:\n\n• Variation of the SOFA score between D7 and D1\n\nSecondary outcomes:\n\n* Death in the ICU\n* Days free of mechanical ventilation within 28 days\n* Days free of vasopressor within 28 days\n* Length of ICU stay\n* Length of hospital stay\n* Renal injury KDIGO \\>= 2 within 7 days\n* Renal replacement therapy use\n* Major bleeding occurency\n* Count of unitis of red blood cells received in 14 days\n\nData management The data will be collected directly from the chart of the patients admitted to the ICU. Data quality assurance will be made through periodic verification, aiming for complete and consistent data. The centers will receive periodic reports for adequacy of potentially inconsistent or incomplete data.\n\nStatistics The baseline SOFA of patients with sepsis is 8.8 with a standard deviation of 3. The expected reduction in the control group in the SOFA at day 7 is 2 points. Considering a power of 80% and a level of significance of 0.05, it is estimated that 109 patients will be needed in each group. A total of 218 patients will compose the sample.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Eligibility - patients:\n\nInclusion criteria:\n\nThe three criteria below must be present:\n\n1. Signature of informed consent\n2. Patients must be older than 18 years old\n3. Diagnosis of sepsis and/or septic shock for less than 48 hours with at least one of the following organ dysfunctions:\n\n * Lactate above 4mmol/L (36mg/dL)\n * Thrombocytopenia \\< 100,000/mm3 or reduction \\> 50% in the count in the last 3 days\n * PaO2/FiO2 \\< 200 without signs of apparent volume overload\n * Hypotension MAP \\< 65mmHg refractory to volume replacement with the need to use vasopressor\n * Acute renal injury increased by 2.0 to 2.9 times from baseline or diuresis rate less than 0.5ml/kg/h for more than 12 hours\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Impossibility to use the intestinal tract\n3. Death perspective in less than 24 hours\n4. Patients in the end of their lives or in exclusive palliative care\n5. Patients with active bleeding\n6. Prior study participation\n7. Known allergy to aspirin\n8. Active peptic ulcer\n9. Previous use of antiplatelet agents in the last 7 days\n10. Previous use of AINEs in the last 7 days, except for dipyrone.\n11. Hemorrhagic stroke in the last 7 days or central nervous system surgery in the last 72 hours.\n12. Platelets \\<30,000 cells/mm3.\n13. Large surgery in the last 24 hours if the attending surgeon judges that the risk of bleeding is high enough that aspirin cannot be used.\n14. Ophthalmologic surgery postoperative and transurethral resection of the prostate at the discretion of the attending physician.\n15. Hepatic cirrhosis or previous liver disease with altered prothrombin activity, manifested by INR above 2.0 or other previous coagulopathies.\n16. Severe head injury in the last 7 days.\n17. Use or indication of anticoagulation'}, 'identificationModule': {'nctId': 'NCT01784159', 'acronym': 'ASP-SEPSIS', 'briefTitle': 'ASpirin for Patients With SEPsis and SeptIc Shock', 'organization': {'class': 'OTHER', 'fullName': 'Federal University of São Paulo'}, 'officialTitle': 'Impact of Aspirin Use on the Severity of Organ Dysfunctions in Patients With Sepsis and Septic Shock: a Randomized, Double-blind, Placebo-controlled Trial - ASP-SEPSIS.', 'orgStudyIdInfo': {'id': 'EPM81449'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo 1tb / day/ 7days', 'interventionNames': ['Drug: Aspirin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Aspirin', 'description': 'Intervention aspirin 200 mg/day for 7 days', 'interventionNames': ['Drug: Aspirin']}], 'interventions': [{'name': 'Aspirin', 'type': 'DRUG', 'otherNames': ['AAS'], 'description': 'Aspirin administration for 7 days', 'armGroupLabels': ['Aspirin', 'Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '04024002', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital São Paulo', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}], 'overallOfficials': [{'name': 'Flavia Machado', 'role': 'STUDY_CHAIR', 'affiliation': 'Federal University of São Paulo'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED', 'description': 'undecided'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Federal University of São Paulo', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor of Intensive Care Medicine', 'investigatorFullName': 'Flavia Ribeiro Machado', 'investigatorAffiliation': 'Federal University of São Paulo'}}}}